Dalvance launch underway

Durata Therapeutics' (DRTX +0.8%) Dalvance (dalbavancin) is now available in the U.S. as a treatment for adult patients with acute bacterial skin and skin structure infections ((ABSSSI)). The company began shipping the antibiotic to distributors this week.

The FDA approved Dalvance on May 23 as a Qualified Infectious Disease Product.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs